Enriched Biomarker‐Driven Clinical Trials

作者: Xiaofei Wang , Jianwen Cai , Stephen L. George

DOI: 10.1002/9781118445112.STAT08153

关键词:

摘要:

参考文章(42)
Stephen L. George, Xiaofei Wang, Targeted Clinical Trials Designs for Clinical Trials. pp. 157- 177 ,(2012) , 10.1007/978-1-4614-0140-7_7
Daniel J. Sargent, Barbara A. Conley, Carmen Allegra, Laurence Collette, Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials Journal of Clinical Oncology. ,vol. 23, pp. 2020- 2027 ,(2005) , 10.1200/JCO.2005.01.112
Boris Freidlin, Edward L. Korn, Biomarker enrichment strategies: matching trial design to biomarker credentials Nature Reviews Clinical Oncology. ,vol. 11, pp. 81- 90 ,(2014) , 10.1038/NRCLINONC.2013.218
Jason Brinkley, Anastasios Tsiatis, Kevin J. Anstrom, A Generalized Estimator of the Attributable Benefit of an Optimal Treatment Regime Biometrics. ,vol. 66, pp. 512- 522 ,(2010) , 10.1111/J.1541-0420.2009.01282.X
Holly Janes, Marshall D. Brown, Ying Huang, Margaret S. Pepe, An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection The International Journal of Biostatistics. ,vol. 10, pp. 99- 121 ,(2014) , 10.1515/IJB-2012-0052
Sue-Jane Wang, H. M. James Hung, Robert T. O'Neill, Adaptive patient enrichment designs in therapeutic trials Biometrical Journal. ,vol. 51, pp. 358- 374 ,(2009) , 10.1002/BIMJ.200900003
Xiaofei Wang, Junling Ma, Stephen George, Haibo Zhou, Estimation of AUC or Partial AUC Under Test-Result-Dependent Sampling Statistics in Biopharmaceutical Research. ,vol. 4, pp. 313- 323 ,(2012) , 10.1080/19466315.2012.692514
Frank Bretz, Heinz Schmidli, Franz König, Amy Racine, Willi Maurer, Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts Biometrical Journal. ,vol. 48, pp. 623- 634 ,(2006) , 10.1002/BIMJ.200510232
Warren J. Strauss, Louise Ryan, Michele Morara, Nicole Iroz-Elardo, Mark Davis, Matthew Cupp, Marcia G. Nishioka, James Quackenboss, Warren Galke, Haluk Özkaynak, Peter Scheidt, Improving cost‐effectiveness of epidemiological studies via designed missingness strategies Statistics in Medicine. ,vol. 29, pp. 1377- 1387 ,(2010) , 10.1002/SIM.3892